The Arvinas ER chimeric degrader, ARV-471 , is an oral, bioavailable ER degrading CRBN-based PROTAC for the treatment of patients with ER+/HER2- breast cancer. Along with ARV-110 , it is one of the first chimeric degraders to enter a Ph. II clinical trial. It was first disclosed at AACR in early 2021, and though the molecules have not been [...]
ARV-471: an Oral ER Degrader for ER+/HER2- Breast Cancer
Arvinas ER Chimeric Degrader
CRBN-based heterobifunctional ER degrader oral Ph. II candidate for ER+/HER2- BC from ER ligand and CRBN ligand ARV-471 Arvinas, New Haven, CT
Loading...
